NEW YORK: Veracyte reported after the close of the market on Wednesday that its fourth quarter revenues rose 16 percent year over year.
For the three months ended Dec. 31, 2020, the South San Francisco, California-based genomics diagnostics firm posted $34.5 million in revenues, up from $29.7 million a year ago and above analysts' average estimate of $31.9 million.